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ABSTRACT In one form of b-thalassemia, a genetic blood
disorder, a mutation in intron 2 of the b-globin gene (IVS2-
654) causes aberrant splicing of b-globin pre-mRNA and,
consequently, b-globin deficiency. Treatment of mammalian
cells stably expressing the IVS2-654 human b-globin gene
with antisense oligonucleotides targeted at the aberrant splice
sites restored correct splicing in a dose-dependent fashion,
generating correct human b-globin mRNA and polypeptide.
Both products persisted for up to 72 hr posttreatment. The
oligonucleotides modified splicing by a true antisense mech-
anism without overt unspecific effects on cell growth and
splicing of other pre-mRNAs. This novel approach in which
antisense oligonucleotides are used to restore rather than to
down-regulate the activity of the target gene is applicable to
other splicing mutants and is of potential clinical interest.
b-Thalassemia, a genetic blood disorder, affects a large num-
ber of people in the Mediterranean basin, Middle East, South
East Asia, and Africa. Close to 100 thalassemic mutations
causing defective b-globin gene expression and b-globin defi-
ciency have been identified, but no more than 10 mutations are
responsible for '90% of cases worldwide (1). Of the fre-
quently occurring mutations, the ones that cause aberrant
splicing of intron 1 of the human b-globin gene are predom-
inant in South Eastern Europe, Cyprus, Lebanon (mutation
IVS1-110), India, Malaysia, and Indonesia (IVS1-5). Addi-
tional splicing mutations in intron 1 (IVS1-6) as well as in
intron 2 of the b-globin gene (IVS2-745) are also common in
the above countries, while IVS2-654 is frequent among
b-thalassemia patients in China and Thailand (1–8). All of
these mutations activate aberrant splice sites and change the
splicing pathway even though the correct splice sites remain
potentially functional. We hypothesized that blocking of the
aberrant splice sites or other sequence elements involved in
splicing with antisense oligonucleotides may force the splicing
machinery to reselect the correct splice sites and induce the
formation of b-globin mRNA and polypeptide, hence restoring
the gene function.
Although we have previously effected correction of splicing
by antisense oligonucleotides in cell-free extracts from HeLa
cells (9), it was not at all clear whether the oligonucleotides
delivered into the cell could enter the nucleus, hybridize to the
aberrant splice sites in competition with the splicing factors,
and promote the formation of the spliceosome and subsequent
splicing at the correct splice site. Here we report that correct
splicing was efficiently restored when phosphorothioate 29-O-
methyl-oligoribonucleotides were targeted to the aberrant
splice sites of IVS2-654 pre-mRNA expressed in mammalian
cells stably transformed with this mutated human b-globin
gene. This is a novel approach since antisense oligonucleotides
have been used mostly as sequence specific down-regulators of
gene expression (10).
MATERIALS AND METHODS
Cells.Human b-globin gene carrying a thalassemic mutation
IVS2-654 was cloned under the cytomegalovirus promoter
(11). The plasmid was cotransfected with a neomycin resis-
tance plasmid by lipofection with Lipofectamine (GIBCOy
BRL) into HeLa and NIH 3T3 cells, and the cells stably
expressing the IVS2-654 b-globin gene were isolated by G-418
antibiotic selection. Control cells expressing the wild-type gene
were obtained in a similar manner. HeLa and NIH 3T3 cell
lines were grown inMEM supplemented with 5% fetal calf and
5% horse sera and in DMEM, high glucose, with 10% filtered
Colorado calf serum, respectively. For all experiments, cells
were plated in 24-well plates at 105 cells per well 24 hr before
treatment.
Oligonucleotide Treatment. The phosphorothioate 29-O-
methyl-oligoribonucleotides (prepared and purified at Hybri-
don) were used. The cells were treated with oligonucleotides
complexed with Lipofectamine for 10 and 6 hr for HeLa and
NIH 3T3 cell lines, respectively (12, 13). In Figs. 1 B and C, 3A,
and 4B, the cells were harvested 36 hr later and were subse-
quently analyzed. The oligonucleotides 59ss-GCUAUUAC-
CUUAACCCAG and 39ss-CAUUAUUGCCCUGAAAG
were targeted to the aberrant 59 splice site and the 39 cryptic
splice site, respectively. Oligonucleotides with random or
scrambled sequences were used as controls. An oligonucleo-
tide, CCUCUUACCUCAGUUACA, targeted to positions
696–713 of b-globin intron 2, encompassing thalassemic mu-
tation IVS2-705 (8), was used as an additional control.
RNA Analysis. Total RNA was isolated with TRI-Reagent
(Molecular Research Center, Cincinnati) and analyzed by
reverse transcription–PCR (RT-PCR) using rTth DNA poly-
merase as suggested by the manufacturer (Perkin–Elmer).
Forward and reverse primers spanned positions 21–43 of exon
2 of the human b-globin gene and positions 6–28 of exon 3,
respectively. The RT-PCR products were separated on 7.5%
nondenaturing polyacrylamide gel. To ascertain that the pro-
tocol is suitable for quantitative analysis, the RT-PCR was
carried out with [a-32P]dATP for no more than 18–20 cycles.
Under these conditions, the amount of the PCR product is
proportional to the amount of input RNA as are the relative
amounts of PCR products generated from aberrantly and
correctly spliced RNA (ref. 14 and data not shown). No
product is detectable without the reverse transcription step.
Protein Analysis. Hemin (10 mM, Fluka) treatment was in
serum-free medium for 4 hr immediately preceding the isola-
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tion of RNA or protein. Blots of proteins separated on a
Tricine-SDSy10% polyacrylamide gel (15) were incubated
with polyclonal affinity-purified chicken anti-human hemoglobin
IgG as primary antibody and rabbit anti-chicken horseradish
peroxidase-conjugated IgG as secondary antibody (Accurate
Chemicals). Subsequently, the blots were developed with the
Enhanced Chemiluminescence detection system (Amersham).
All autoradiograms were captured by a DAGE–MTI (Mich-
igan City, IN) CCD72 video camera, and the images were
processed using National Institutes of Health IMAGE 1.47 and
MACDRAW PRO 1.0 software. The IMAGE 1.47 was also used for
quantitation of the autoradiograms. The final figures were
printed on Tektronix phaser 440 printer.
RESULTS
Since appropriate cellular or animal models of thalassemic
splice mutants are not available, we have constructed two cell
lines stably transformed with the IVS2-654 variant of the
thalassemic human b-globin gene. In a HeLa-based cell line,
as in thalassemic patients (1, 3, 4), this mutation created a 59
splice site at nucleotide 652 of intron 2 and activated a 39
cryptic splice site 73 nucleotides upstream, resulting in stably
expressed but aberrantly spliced IVS2-654 b-globin pre-
mRNA (Fig. 1 A and B, lane 2). To restore correct splicing of
the RNA, the cells were treated for 10 hr with a complex of
Lipofectamine and the 18-mer phosphorothioate 29-O-methyl-
oligoribonucleotide (59ss) targeted to the aberrant 59 splice
site. The 29-O-methyl derivatives were chosen since they
hybridize well to their target sequences and are very stable in
cellular environment. Moreover, importantly, in contrast to
commonly used oligodeoxynucleotides or phosphorothioate
oligodeoxynucleotides, they do not promote cleavage of hy-
bridized RNA by cellular RNase H (17). The latter property is
the key condition for the success of the experiments since
treatment with an unmethylated oligonucleotide would have
led to degradation of the b-globin pre-mRNA and removal of
the splicing substrate (10, 18).
Fig. 1B shows that treatment with 29-O-methyl phosphoro-
thioates was effective in blocking the aberrant splice site and
restoring correct splicing of b-globin pre-mRNA. Quantitative
RT-PCR analysis (ref. 14; see Materials and Methods) of the
RNA showed that the amount of correctly spliced b-globin
mRNA increased in a dose-dependent fashion, and at 0.05, 0.1,
and 0.2 mM oligonucleotide reached, respectively, 16, 24, and
34% of the total (Fig. 1B, lanes 3–5 and Table 1). There was
no further increase in the correctly spliced product at 0.4 mM
oligonucleotide (33%), while treatment at 0.6 mM oligonucle-
otide drastically lowered its amount (Fig. 1B, lanes 6 and 7,
respectively). The latter result is possibly due to the fact that
the ratio of Lipofectamine:nucleic acid deviated from a narrow
range necessary for efficient cellular uptake of the complex
(13). The effect of the antisense oligonucleotide was sequence-
dependent since control oligonucleotides either with random
or with scrambled sequences (Fig. 1B, lanes 11–13) did not
restore correct splicing. Somewhat weaker correction of ab-
errant splicing of IVS2-654 pre-mRNA (11%) was obtained
when the cells were treated with a 17-mer oligonucleotide
antisense to the 39 cryptic splice site activated by the IVS2-654
mutation (see Table 1). Note that in untreated (Fig. 1B, lane
2) or control (Fig. 1B, lanes 11–13) cells, there was no
detectable PCR product representing the correctly spliced
b-globin mRNA. Therefore, in both 59ss and 39ss oligonucle-
otide-treated cells the b-globin mRNAmust have been spliced
de novo and the observed band could not have resulted from
preferential RT-PCR amplification of a preexisting shorter,
correctly spliced mRNA.
Analysis of the total protein from oligonucleotide-treated
cells by immunoblotting with polyclonal antibody to human
hemoglobin showed that the newly generated, correctly spliced
b-globin mRNA was translated into full-length b-globin. In
agreement with the RT-PCR results shown in Fig. 1B, only
samples treated with 0.05–0.4 mM oligonucleotide contained
significant amounts of full-length b-globin (Fig. 1C, lanes 3–6).
FIG. 1. (A) Splicing of human b-globin IVS2-654 pre-mRNA in the
presence of an antisense oligonucleotide. Boxes, exons; solid lines,
introns; dashed lines, both correct and aberrant splicing pathways;
thick bar, oligonucleotide antisense to the aberrant 59 splice site; thin
bars above and below exon sequences, primers used in the RT-PCR
reaction. The aberrant 59 splice site created by IVS2-654 mutation and
the cryptic 39 splice site activated upstream are indicated. (B) Cor-
rection of splicing of IVS2-654 pre-mRNA in HeLa cells by antisense
oligonucleotide targeted to the aberrant 59 splice site (59ss). Analysis
of total RNA by RT-PCR. Lanes: 1, wild-type (WT) HeLa cells; 8,
HeLa cell line expressing normal human b-globin (bg); 14, RNA from
human blood (Hb); 2–7, IVS2-654 HeLa cells treated with increasing
concentrations of the oligonucleotide (indicated in micromoles at the
top); 9 and 10, IVS2-654 HeLa cells treated with oligonucleotide
followed by hemin (H) (16); 11–13, IVS2-654 HeLa cells treated with
increasing concentrations of the scrambled oligonucleotide. The num-
bers on the right indicate the size, in nucleotides, of the RT-PCR
products representing the aberrantly (304) and correctly (231) spliced
RNAs. (C) Restoration of b-globin expression by 59ss oligonucleotide
in IVS2-654 HeLa cells. Immunoblot of total protein with anti-human
hemoglobin antibody. Concentration of the oligonucleotide in micro-
moles is indicated at the top (lanes 2–7); in lane 8, human globin
(Sigma) was used as a marker. (Lower) Cells were treated with hemin
preceding the isolation of proteins. The positions of human b-globin
and the prematurely terminated b-globin IVS2-654 polypeptide are
indicated. Time of exposure of the autoradiogram in Lower was 1y5th
of that of the Upper.
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There was no b-globin in control cells (Fig. 1C, lanes 1 and 2)
and only a small amount in those treated with 0.6 mM
oligonucleotide (Fig. 1C, lane 7). Thus, the significant increase
in full-length b-globin, roughly parallel to that of the b-globin
mRNA, is clearly due to the effect of antisense oligonucleo-
tides on splicing. The quantitative analysis of the amount of the
b-globin polypeptide relative to the one truncated due to
aberrant splicing (in the aberrant sequence the stop codon is
located 48 nucleotides downstream from exon 2, resulting in a
b-globin polypeptide containing 104 b-globin and 16 aberrant
amino acids) shows that the amount of b-globin increases from
'30% of the total at 0.05 mM oligonucleotide to 43% at 0.2
mM and 44% at 0.4 mM oligonucleotide. The fact that the
percentage of b-globin protein seems to be slightly higher than
that of the corresponding correctly spliced mRNA may pos-
sibly be due to the differences in the relative stabilities of the
correct and aberrant polypeptides. Nevertheless, the yields of
correct protein provide evidence that the amount of the
correctly spliced b-globin mRNA is not overrepresented in the
RT-PCR assay.
The identity of the generated full-length b-globin polypep-
tide band was confirmed by the increase in its intensity upon
posttreatment of the cells with hemin (Fig. 1C Lower, lanes
3–6) (16). Note that hemin treatment had no effect on the
truncated IVS2-654 polypeptide or background protein bands
(Fig. 1C Upper and Lower, lanes 2–7). Neither did it affect the
level of transcription and splicing pattern of the IVS2-654
pre-mRNA (Fig. 1B, lanes 9 and 10). Thus, the increase in
b-globin band due to hemin is not the result of activation of
globin gene expression, observed for fetal globin genes in
hematopoietic cell lines (e.g., ref. 19 and references therein).
It seems likely that the polyclonal anti-hemoglobin antibody
has greater affinity for the b-globin-heme complex than for
b-globin alone andyor that hemin treatment results in specific
posttranslational stabilization of the full-length b-globin (20).
Fig. 2 shows the time course of restoration of correct splicing
of b-globin pre-mRNA and its translation to protein after
treatment with 0.2 mM 5’ss oligonucleotide. Six hours after
termination of the treatment, there was a trace, if any, of the
correct b-globin mRNA and protein (Fig. 2 A, lane 3, and B,
lane 2, respectively) that increased significantly at 24 hr and
persisted for 48 but not 96 hr (Fig. 2 A, lanes 4–6, and B, lanes
3–5). The b-globin signal was, as expected, stimulated by
hemin treatment of the cells (Fig. 2B, lane 6 versus lane 3). The
fact that correctly spliced RNA persisted for 48 hr after
termination of oligonucleotide delivery suggests that the oli-
gonucleotides andyor the newly synthesized correctly spliced
mRNA are quite stable in the cellular environment. It is also
possible that the oligonucleotide is recycled after the spliced
out intron is degraded (21).
To test whether oligonucleotides are able to reverse aberrant
splicing in other cell types, analogous experiments were per-
formed using NIH 3T3 cells stably transfected with the IVS2-
654 b-globin gene. Since 10 hr incubation in the serum-free
medium (used for HeLa cells) was damaging for the NIH 3T3
cells, the treatment was shortened to 6 hr. Even with the
shortened treatment, 59ss oligonucleotide targeted to the
aberrant 59 splice site in IVS2-654 pre-mRNA produced
correctly spliced b-globin mRNA at levels'3-fold higher than
those observed for HeLa cells treated with the same oligonu-
cleotide for the same time (Table 1). As expected, the effects
of the oligonucleotide were dose- and sequence-dependent
(Fig. 3A).
Repair of aberrant splicing was also obtained, albeit not as
efficiently, by targeting the 39 cryptic splice site (Fig. 3B and
Table 1). This indicates that the relative accessibility of the 39
versus 59 splice site is similar in both HeLa and NIH 3T3 cells.
The time course of the reaction (Fig. 3B) suggests that there
is no major difference in the stability of the b-globin mRNA
and of the two oligonucleotides in the two cell types.
Although the above results clearly show that the oligonu-
cleotides affect splicing of their target pre-mRNAs in a
sequence specific manner, one cannot exclude the possibility
that they may exert other effects on the cells. The oligonucle-
otides may interact directly with cellular proteins (ref. 22 and
references therein) or, possibly, inhibit gene expression by
blocking similar splice sites in many other pre-mRNAs and
consequently inhibit the growth of cells. However, the results
presented in Fig. 4 show that under our experimental condi-
tions no unspecific effects were detectable. First, the growth
rate of the HeLa IVS2-654 cells treated with the Lipo-
fectamine–oligonucleotide complex was no different from that
of cells treated with Lipofectamine alone (Fig. 4A). The
oligonucleotides tested included 29-O-methyl phosphorothio-
ates complementary to the aberrant splice sites or with a
scrambled sequence as well as 59ss and 39ss 29-O-methyl
phosphodiesters. Second, the 59 ss oligonucleotide that re-
stored correct splicing in HeLa IVS2-654 (Fig. 4B, lane 6) had
no effect on splicing of HeLa cells transfected with a control
construct in which the target aberrant 59 splice site
(GUAAUA) was modified to match the consensus splice site
sequence (GUAAGU; ref. 23) (Fig. 4B, lanes 2–4). This
FIG. 2. Time course of restoration of correct splicing and b-globin
expression in HeLa IVS2-654 cells by 0.2 mM 59ss oligonucleotide. (A)
RT-PCR assay. (B) Immunoblot. Time after termination of oligonu-
cleotide treatment is indicated at the top. H, hemin treatment of the
cells. All other designations are as in Fig. 1.









HeLa 59ss* 43 (protein)
HeLa 39ss* 11
NIH 3T3 59ss† 49
NIH 3T3 39ss† 23
The results of the treatment with 0.2 mM antisense oligonucleotides,
the concentration that elicits maximal correction in all experiments,
are shown. The amount of the material in the correct PCR product or
in b-globin protein band was quantitated by densitometry of the
autoradiograms as described. The results are expressed as percent of
the correct product relative to the sum of correct and aberrant
products.
*Treatment with oligonucleotide was for 10 hr.
†Treatment with oligonucleotide was for 6 hr.
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modification resulted in a two nucleotide mismatch of the
oligonucleotide with 16 nucleotides remaining complementary
to the intron sequence. Third, splicing of IVS2-654 pre-mRNA
was not affected in cells treated with an oligonucleotide with
partial complementarity to the region of the aberrant 59 splice
site (slash indicates splice site):
pre-mRNA 59 CUGGGUUAAGy UAAUAGC
u u u u u u u u u u u u
oligo 705 39 ACAUUGACUCy AUUCUCC
Moreover, this oligonucleotide, designed to restore correct
splicing of IVS2-705 thalassemic mutant (ref. 8; unpublished
work) is also complementary, with a single mismatch, to
positions 696–713 of IVS2, 44 nucleotides downstream from
the aberrant 59 splice site (Fig. 4B, lanes 8–10).
Since the closely related IVS2-654 consensus splice site is
unaffected by the 59ss oligonucleotide, and a related oligonu-
cleotide, oligo 705, with partial complementarity to two sites
in the same RNA has no effect on splicing of IVS2-654
pre-mRNA, the likelihood that the 59ss oligonucleotide would
affect splicing of other pre-mRNAs with even more divergent
sequences at and around the splice sites appears quite remote.
This is further reinforced by the fact that we have not detected
any changes in the level andyor the splicing patterns of two
randomly chosen mRNAs (b-actin and EGFR) in cells treated
with the 59ss oligonucleotide (not shown) and by the data from
GenBank that show lack of complementarity of any human
sequence besides b-globin to the 59ss and 39ss oligonucleotides,
even if two mismatches are allowed.
DISCUSSION
We showed that splicing pathways can be modified in vivo in
a sequence specific manner by antisense oligonucleotides using
cationic liposomes as a carrier. In view of the universal nature
of the splicing mechanisms, this approach is of general appli-
cability because the oligonucleotides should be effective in
different cell types, including hematopoietic cells, and against
splice sites in a variety of pre-mRNAs.
Although the feasibility of treatment of thalassemics with
antisense oligonucleotides has yet to be explored, several
observations suggest that this approach may be clinically
promising. The optimal effect of oligonucleotides was seen at
0.2–0.4 mM, a concentration achieved in bone marrow of
experimental animals (24). Restoration in a patient of b-globin
mRNA to 20–30% of the normal level would be of therapeutic
significance because heterozygotes with 50% of hemoglobin
are frequently asymptomatic while the status of patients
undergoing transfusion therapy, with even lower hemoglobin
FIG. 3. Dose- and time-dependent correction of splicing in oligo-
nucleotide-treated IVS2-654 NIH 3T3 cells. RT-PCR assay. (A) Cells
treated with increasing concentrations of the oligonucleotide targeted
to the aberrant 59 splice site (Upper) or of the control, scrambled
oligonucleotide (Lower). (B) Time course of the correction of splicing
after termination of treatment with 0.2 mM oligonucleotide targeted
to the cryptic 39 splice site activated by the IVS2-654 mutation. All
designations are as in Figs. 1 and 2.
FIG. 4. Specificity of oligonucleotide treatments. (A) Lack of effect
of oligonucleotides on cell growth. HeLa IVS2-654 cells were treated
with Lipofectamine–oligonucleotide complexes as described. Cells
were counted at the end of the 10 hr treatment (0 hr) and at 24, 52,
and 72 hr thereafter. Each point on the curve represents the average
of duplicate counts of two independently treated samples; the ob-
served differences are within experimental error (one SD). M, Lipo-
fectamine alone. The remaining samples were treated with Lipo-
fectamine complexed with the following 0.2 mM oligoribonucleotides:
29-O-methyl phosphorothioates,L, 59ss, 3, 39ss,l, scrambled; 29-O-
methyl phosphodiesters, Ç, 59ss, m, 39ss. (B) Lack of effect of control
oligonucleotides. Treatment of HeLa IVS2-654 consensus cell line
(lanes 1–4, see text) or HeLa IVS2-654 cell line (lanes 5 and 6, as
positive control) with 59ss 29-O-methyl phosphorothioate oligoribo-
nucleotide. Lanes 8–10, treatment of HeLa IVS2-654 cells with
oligonucleotide 705 targeted 44 nucleotides downstream from the
aberrant 59 splice site (see text). The RT-PCR assay and all designa-
tions are as described in the legend to Fig. 1B. Lane 7, HeLa cell line
expressing normal human b-globin.
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levels, is markedly improved. Furthermore, b-globin mRNA
and protein are very stable and so are mature erythrocytes,
with a lifespan of about 120 days (1). Thus, in principle,
treatment with antisense oligonucleotides may have an ex-
tended effect on the in vivo levels of b-globin mRNA and blood
hemoglobin, reducing the need for frequent administration. In
this context, it is encouraging that the correctly spliced b-glo-
bin mRNA and protein generated by a single delivery of the
antisense oligonucleotide persisted in NIH 3T3 and HeLa cells
for up to 48 hr. Moreover, the fact that it was possible to
effectively deliver the oligonucleotides to the nuclei of various
cell types suggests that it should be feasible to find appropriate
conditions andyor carriers for delivery of the oligonucleotides
into cells of patients, including the targeted nucleated eryth-
roblasts. The effects of antisense oligonucleotides should be
highly specific because only the latter cells contain the target
sequence.
The restoration of correct splicing by targeting the cryptic 39
splice site (Fig. 3B) is of particular interest since this splice site
is activated in other b-thalassemia mutations besides IVS2-
654, i.e., IVS2-745 and IVS2-705 (1, 8). Thus, a single oligo-
nucleotide should be effective in correcting splicing in all three
mutants, which in clinical setting would translate into a larger
number of patients. It is also likely that aberrant splice sites
activated by other thalassemic mutations (1, 2) will be ame-
nable to this approach. Since splicing mutations are respon-
sible for a large proportion of b-thalassemia patients (2), it
appears that restoration of correct splicing of b-globin pre-
mRNAmay offer a useful alternative to current treatments (1)
and to potential therapies based on stimulation of fetal he-
moglobin production (25, 26) or b-globin gene transfer.
The specificity of phosphorothioate antisense oligonucleo-
tides and their mechanism of action were recently questioned
(22). However, several lines of evidence indicate that in this
work correction of splicing occurred by a true antisense
mechanism. The effects were sequence specific because only
the oligonucleotides targeted to the splice sites but not the
control ones (random and scrambled) restored correct splic-
ing. The oligonucleotide complementary to the aberrant 59
splice site in IVS2-654 pre-mRNA had no corrective effect on
splicing in HeLa cells of a modified, control IVS2-654 con-
sensus construct. There was likewise no corrective effect of an
oligonucleotide (oligo 705) that can hybridize to another site
of the intron, indicating that the region around the splice sites
is essential as a specific target. The same oligonucleotide shows
that hybridization with less than 17 consecutive nucleotides
gives no antisense effect, indicating that it is unlikely that
splicing of unrelated pre-mRNAs may be affected to a signif-
icant degree by oligonucleotides targeting IVS2-654. The lack
of multiple unspecific effects is also supported by the obser-
vation that none of the tested oligonucleotides affected the
growth rate of the treated cells. Correction of splicing was
observed with 29-O-methyl-oligoribonucleotides both with and
without the phosphorothioate modification (not shown) in
IVS2-654 HeLa and NIH 3T3 cells, i.e., regardless of cell type
and species. Hence, it seems highly unlikely that the effects of
phosphorothioate oligonucleotides were caused by their direct
interaction with a cellular protein as observed in several other
investigations (ref. 22 and references therein).
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